SAVA
Cassava Sciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
SAVA Profile
Cassava Sciences, Inc.
A clinical-stage biotechnology company focused on Alzheimer’s disease
Pharmaceutical
Invalid Date
07/14/2000
NASDAQ Stock Exchange
30
12-31
Common stock
6801 N. Capital of Texas Highway, Building 1, Suite 300, Austin, TX 78731
--
Cassava Sciences, Inc., is a biopharmaceutical company dedicated to the development of new drugs. The company's main drug candidate is called oxycodone (oxycodone) sustained-release capsules. Oxycodone is a powerful pain reliever, and its unique formulation helps reduce the potential threat of unplanned doses. Oxycodone and three other non-abuse painkillers were developed in cooperation with King Pharmaceuticals, Inc., and under a license agreement (Pfizer Agreements). King Pharma, Inc., is a subsidiary of Pfizer, Inc. The company was incorporated in Delaware in May 1998.